×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

Eli Lilly India receives permission for emergency use of antibody drugs combination for COVID

  670 Views

eMediNexus    02 June 2021

Eli Lilly and Company India has been granted permission for emergency use of its antibody drugs combination for the treatment of mild to moderate COVID-19 in India.

Permission has been given for restricted emergency use of the monoclonal antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, given together in patients with mild to moderate COVID-19, stated the company. The combination of bamlanivimab and etesevimab has been given Emergency Use Authorization in the US and some EU countries as well, for the treatment of the viral disease. 

In May, the company was granted permission for the emergency use of baricitinib along with remdesivir, to treat suspected or laboratory confirmed COVID-19 in the country… (ET Healthworld – PTI, June 2, 2021)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.